Archives of Obesity and Metabolism (비만대사연구학술지)

The Study of Obesity and Metabolic Syndrome, KAFM (대한가정의학회 비만대사증후군연구회)
권호 표지
DOI QR코드

DOI QR Code

Low-Dose Off-Label Use of Phentermine/Topiramate in the Individual with Morbid Obesity and Postoperative Hypothyroidism

수술 후 갑상선기능저하가 동반된 고도비만환자의 펜터민염산염/토피라메이트의 저용량 오프라벨 사용

  • Park, Jung Ha (Department of Family Medicine, Jeju National University Hospital)
  • 박정하 (제주대학교병원 가정의학과)
  • Received : 2022.05.03
  • Accepted : 2022.06.15
  • Published : 2022.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Intensive lifestyle modifications and anti-obesity medications are essential for obesity treatment. Antiobesity medications should be selected according to the patient's comorbidities, symptoms, and preferences. This case report describes the treatment of a morbidly obese patient with a history of depression, who complained of tingling and numbness after total thyroidectomy for papillary thyroid cancer. Very low-dose controlled-release phentermine/topiramate was prescribed and intensive lifestyle modifications were encouraged. As a result, the patient effectively lost weight and reached a near-normal weight without adverse drug effects. This implies that even an off-label anti-obesity medication low dose may be better for some patients, and the most important factor in obesity treatment is patient-tailored treatment.

Keywords

References

  1. Cho SH, Kim KK. Obesity treatment in ambulatory care focused on pharmacotherapy. Korean J Fam Pract 2020;10:77-86. https://doi.org/10.21215/kjfp.2020.10.2.77
  2. Karam JG, McFarlane SI. Secondary causes of obesity. Therapy 2007;4:641-50. https://doi.org/10.2217/14750708.4.5.641
  3. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012;20:330-42. https://doi.org/10.1038/oby.2011.330
  4. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341-52. Erratum in: Lancet 2011;377:1494. https://doi.org/10.1016/S0140-6736(11)60205-5
  5. De Lorenzo A, Gratteri S, Gualtieri P, Cammarano A, Bertucci P, Di Renzo L. Why primary obesity is a disease? J Transl Med 2019;17:169. https://doi.org/10.1186/s12967-019-1919-y
  6. Pasquali R, Casanueva F, Haluzik M, et al. European Society of Endocrinology Clinical Practice Guideline: endocrine work-up in obesity. Eur J Endocrinol 2020;182:G1-32. https://doi.org/10.1530/eje-19-0535